<DOC>
	<DOCNO>NCT01292421</DOCNO>
	<brief_summary>RATIONALE : Hepatitis B antigen peptide ( HBsAg ) vaccine may help body build immune response help prevent hepatitis B . PURPOSE : This clinical trial study edible HBsAg vaccine therapy healthy participant undergo previous vaccination .</brief_summary>
	<brief_title>Edible Hepatitis B Vaccine Therapy Healthy Participants Who Have Undergone Previous Vaccination</brief_title>
	<detailed_description>OBJECTIVES : I . To evaluate safety , tolerability , immunogenicity orally deliver HBsAg formulate express protein transgenic potato tuber ( HBV-EPV ) different dos schedule . OUTLINE : Patients randomize 1 4 treatment arm . ARM I : Participants consume placebo HBV-EPV day 0 , 14 , 28 , 56 . ARM II : Participants consume HBV-EPV express HBsAg day 0 28 placebo HBV-EPV day 14 56 . ARM III : Participants consume HBV-EPV express HBsAg day 0 , 28 , 56 placebo HBV-EPV day 14 . ARM IV : Participants consume HBV-EPV express HBsAg day 0 , 14 , 28 , 56 . After completion study treatment , patient follow day 70 , 84 , 98 , 114 .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>All Roswell Park Cancer Institute ( RPCI ) staff , faculty , student , good health Participants confirmation history primary immunization series recombinant hepatitis B ( HB ) vaccine ( last dose least one year prior screen antiHBs level assessment ) Current antiHBs level less equal 115 mIU/mL Major organ function within acceptable medical limit determine routine clinical laboratory screen test Expected availability duration study period If female , documentation subject pregnant acceptable laboratory test subject use adequate birth control method prevent pregnancy least 3 month follow last immunization study Human immunodeficiency virus ( HIV ) antibody negative Ability provide write informed consent Supervisor approval Known history allergy hypersensitivity potato , potato component potato product Known history allergy hepatitis B vaccine form component hepatitis B vaccine Pregnancy breast feed Current antiHBS level great 115 mIU/mL Known immunodeficiency , cancer , use immunosuppressive medication include cancer chemotherapy systemic steroid ( exclude intermittent use topical steroid ) Participation another investigational study within 30 day enrollment study Known currently active gastrointestinal disease include follow : peptic ulcer disease , gastroesophageal reflux , inflammatory bowel disease , diverticulitis , pancreatitis Use prescription medication counter H2 blocker proton pump inhibitor ( PPIs ) diseases regularly within 1 month enrollment Diagnosis insulindependent diabetes multiple sclerosis Significant laboratory abnormality suggest dysfunction hematological , renal , hepatic system Known history hepatitis B infection past Temporary exclusion mild upper respiratory illness , gastrointestinal illness , febrile episode expect document resolve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>